Cart
sales@molnova.com
(Rac)-JBJ-04-125-02
CAS No. 2140807-05-0
(Rac)-JBJ-04-125-02( —— )
Catalog No. M23974 CAS No. 2140807-05-0
JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 262 | In Stock |
|
| 5MG | 217 | In Stock |
|
| 10MG | 353 | In Stock |
|
| 25MG | 598 | In Stock |
|
| 50MG | 833 | In Stock |
|
| 100MG | 1135 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(Rac)-JBJ-04-125-02
-
NoteResearch use only, not for human use.
-
Brief DescriptionJBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
-
DescriptionJBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR (L858R/T790M )
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2140807-05-0
-
Formula Weight543.6
-
Molecular FormulaC29H26FN5O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO:240mg/mL (441.5 mM);Water:Insoluble
-
SMILESC1CN(CCN1)C2=CC=C(C=C2)C3=CC4=C(CN(C4=O)C(C5=C(C=CC(=C5)F)O)C(=O)NC6=NC=CS6)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
molnova catalog
related products
-
EGFR-IN-11
EGFR-IN-11 is a selective inhibitor of EGFR-tyrosine kinase and induces cell apoptosis. EGFR-IN-11 inhibits triple mutant EGFRL858R/T790M/C797S with an IC50 of 18 nM and arrests cell cycle at G0/G1.
-
E4CPG
E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.
-
Varlitinib
Varlitinib is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM respectively. Phase 2.
